PipelineReview.com17h
REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
ROCKVILLE, MD, USA I October 21, 2024 I REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from the Phase II fellow eye sub-study evaluating the ...
PipelineReview.com17h
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
VANCOUVER, Canada I1, 2024 I Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, ...
PipelineReview.com17h
Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial
BAGSVAERD, Denmark I1, 2024 I Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, ...
PipelineReview.com17h
Find Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of FTX-101
MONTREAL, Canada I1, 2024 I Find Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies ...
PipelineReview.com3d
Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study
The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with DME ...
PipelineReview.com5d
SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating theCompany’s Lead Development Program SR-878
Transition into clinical-stage development marks a significant corporate and R&D milestone.
PipelineReview.com4d
Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor
CHENGDU, China I October16, 2024 I Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license ...
PipelineReview.com4d
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
SOUTH SAN FRANCISCO, CA, USA I October 17, 2024 I Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative ...
PipelineReview.com6d
IsomAb Announces Nomination of Development Candidate for Peripheral Arterial Disease and Strategic Collaboration with Pfizer
ISM-001 is a potential first-in-class antibody that may lead to a new treatment pathway for patients with peripheral arterial ...
PipelineReview.com4d
Clarametyx Biosciences Announces Progress on Study of Antibody Therapy CMTX-101 for Infections Associated With Cystic Fibrosis
Following successful Phase 1b completion, Clarametyx is initiating the Phase 2a portion to assess CMTX-101 as an adjunct to standard of care for chronic ...